

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



IP Receptor (H237) Peptide

Cat No.: BS3196P

Background

Cyclooxygenases metabolize arachidonate to five primary prostanoids: PGE₂, PGF₂ α , PGI₂, TXA₂ and PGD₂. These lipid mediators interact with specific members of G protein-coupled prostanoid receptors, designated EP, FP, IP, TP and DP, respectively. The IP Receptor binds prostacyclin, PGI₂, the main prostanoid synthesized by vascular tissues. First discovered in 1976, prostacyclin is involved in platelet aggregation inhibition, vasodilatation and cytoprotection, and either prostacyclin or its analogs are used in the treatment of hypertension. Upon binding to the IP Receptor, prostacyclin activates adenylate cyclase primarily through the Gas protein. The gene encoding the human IP Receptor is located on chromosome 19. It is expressed as a glycosylated and phosphorylated protein, which is abundantly expressed in vascular tissues such as aorta, lung, atrium and ventricle, as well as in kidney, thymus, spleen and neurons.

Swiss-Prot

P43119

Applications

Blocking

Specificity

This peptide can be used with studies using BS3196 IP Receptor (H237) pAb.

Purification & Purity

Synthetic peptide IP Receptor (H237). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.

1660 South Highway 100, Suite 500 St. Louis Park, MN

55416, USA.

Email: info@bioworld.com

Tel: 6123263284

Fax: 6122933841

Bioworld technology, co, Ltd.

No 9, weidi road Qixia District Nanjing, 210046,

P, R.China.

Email: info@biogot.com

Tel: +86-025-68037686

Fax: +86-025-68035151